Twist Bioscience Corp (TWST) financials
Twist Bioscience revenue and earnings by year
Twist Bioscience's revenue was $377 million in the fiscal year to September 30, 2025, up 20.3% from the year before. Net income was -$77.7 million, -20.6% of revenue. Since the fiscal year to September 30, 2016, revenue has grown 76.5% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 377 | 313 | 245 | 204 | 132 | 90 | 54 | 25 | 11 | 2 |
| Revenue growth | 20.3% | 27.7% | 20.4% | 53.8% | 46.9% | 65.7% | 113.9% | 136.2% | 374.5% | — |
| Gross profit | 191 | 133 | 90 | 84 | 52 | 29 | 7 | -7 | -13 | -7 |
| Gross margin | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | 31.8% | 12.8% | -26.6% | -123.1% | -315.2% |
| Operating income | -136 | -221 | -217 | -235 | -153 | -140 | -109 | -71 | -58 | -44 |
| Operating margin | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% | -155.5% | -200.1% | -277.5% | -543.2% | -1924.0% |
| Net income | -78 | -209 | -205 | -218 | -152 | -140 | -108 | -71 | -59 | -44 |
| Net margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | -155.3% | -198.0% | -280.2% | -550.8% | -1943.1% |
| Diluted EPS | -$1.30 | -$3.60 | -$3.60 | -$4.04 | -$3.15 | -$3.69 | -$3.98 | -$25.51 | — | — |
| Free cash flow | -76 | -69 | -170 | -226 | -139 | -152 | -103 | -70 | -58 | -45 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open TWST in Markets.
How Twist Bioscience makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Ngs Tools | $61.8M | 52.2% |
| Antibody Discovery | $56.6M | 47.8% |
See also: TWST returns
No forecast, no recommendation. This page describes Twist Bioscience Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.